Table 1.

MIF Directed Therapeutics

Small molecule inhibitors.
Name:	Description:	Target:	Reference:
N-Acetyl-P-benzoquinone (NAPQI)	Metabolite of acetaminophen/paracetamol	MIF tautomerase site	105
ISO-1	4,5-dihydro-3-(4-hydroxyphenyl)-5-isoxazoleacetic acid methyl ester	MIF tautomerase site	32, 106, 107
4-IPP	4-Iodo-6-Phenylpyrimidine	MIF tautomerase site	108–112
SCD-19	Isocoumarin	MIF tautomerase site	113, 114
Ibudilast	3-isobutyryl-2-isopropylpyrazolo-(1,5-a) pyridine	MIF, proximal to the tautomerase site	112, 115, 116
Ebselen	Synthetic organo-selenium	MIF trimer	117
p425	Azo sulfonated organic acid	MIF trimer	118
Monoclonal antibodies.
Name:	Description:	Target:	Reference:
imalumab	Human monoclonal	MIF	121
milatuzumab	Humanized monoclonal	CD74	122–128
Peptide inhibitors.
Name:	Description:	Target:	Reference:
DRα1-MOG-35–55	HLA-DRα1 domain and myelin oligodendrocyte glycoprotein 35–55 peptide	CD74	131
RTL1000	HLA-DRα1β1 and myelin oligodendrocyte glycoprotein 35–55 peptide	CD74	132, 133
C36L1 peptide	Immunoglobulin complementarity-determining region (CDR) peptide	CD74	135
MIF-(40-49), MIF-(47-56)	Resemble the N-like loop of MIF that binds to CXCR2	CXCR2	136

MIF: macrophage migration inhibitory factor protein;

HLA: human leukocyte antigen;

MOG: myelin oligodendrocyte glycoprotein